RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and XLV (0.08% expense ratio) may be more suitable for cost-conscious investors seeking lower-risk options.

The Vanguard S&P 500 ETF (VOO) has become heavily concentrated in mega-cap tech stocks, with its top 10 holdings accounting for nearly 40% of assets and surpassing dot-com bubble concentration levels. The Invesco S&P 500 Equal Weight ETF (RSP) offers an alternative by weighting all 500 S&P 500 stocks equally, reducing concentration risk. While VOO has delivered strong returns driven by AI enthusiasm, the author suggests switching to RSP if concentration exceeds 50% to protect against potential AI stock corrections.

The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.

The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

Nadja West, a director at Tempus AI, sold 3,000 shares for $161,700 on August 14 under a pre-established Rule 10b5-1 trading plan set up in May. Four days later, the stock rallied 24% following news that Moderna and Merck's cancer vaccine succeeded in late-stage trials. West retained 34,981 shares worth ~$1.8 million. The sale timing appears coincidental as it was scheduled months in advance, and the company reported strong Q2 results with 22% revenue growth and its first GAAP profit.

Tempus AI's Chief Legal Officer Andrew Polovin sold 30,075 shares worth $1.5 million in a non-discretionary transaction to cover tax withholding obligations from RSU vesting. The sale occurred during a 75% stock rally driven by positive results from a Moderna-Merck cancer vaccine trial validating Tempus's genomic sequencing technology. The company reported 22% revenue growth to $382.5 million last quarter and achieved its first GAAP profit, though it remains unprofitable on a TTM basis with -$254.4 million net income.

Ionis Pharmaceuticals CEO Brett Monia discusses the company's progress in 2026, highlighting FDA approval for Tryngolza and upcoming results for Pelacarsen in heart disease treatment. The company targets cash flow break-even in 2028 and projects $7 billion in peak revenue from late-stage programs. With 13 neurology drugs in clinical trials, Ionis aims to establish itself as a leader in antisense technology beyond first-mover competitors.

Moderna and Merck announced positive Phase 3 clinical trial results for intismeran, an mRNA-based cancer therapy designed to activate anti-tumor immune responses in melanoma patients. The experimental treatment met its primary endpoint of recurrence-free survival when combined with Merck's Keytruda immunotherapy. The companies plan to present additional data and seek regulatory approval, positioning them to capture a larger share of the $275 billion global oncology market by 2030.

Moderna and Merck announced successful Phase 3 trial results for a personalized mRNA cancer vaccine combined with Merck's Keytruda immunotherapy. The treatment showed melanoma patients experienced longer periods before cancer recurrence and reduced spread compared to Keytruda alone. This marks the first Phase 3 success for mRNA cancer therapy and individualized neoantigen therapy, with both companies planning to present findings to regulators.

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.

Moderna's stock has surged nearly 90% in 2026, driven by positive FDA news about its flu vaccine mRNA-1010 in June. However, the rally appears unjustified as the vaccine is unlikely to generate significant revenue ($1B by 2028) and the company faces fundamental challenges including $3.4B in operating losses over the trailing 12 months, declining revenue, and dependence on COVID vaccine sales. With a $20B+ market cap and limited compelling growth catalysts beyond the experimental cancer vaccine mRNA-4157, the stock appears overvalued for its risk profile.